FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients treated with Eylea in the MYRROR study (one injection given at start of therapy, with additional injections given in case of disease persistence or recurrence), CRT decreased soon after treatment initiation favouring Eylea at week 24 (-79 microns and -4 microns for the Eylea 2 mg treatment group and the control group, respectively), which was maintained through week 48.
Slovenian: Pri bolnikih, zdravljenih z zdravilom Eylea, v študiji MYRROR (ena injekcija na začetku zdravljenja, dodatne injekcije pa v primeru vztrajanja bolezni ali ponovitvi), se je kmalu po začetku zmanjšala CRT, v korist zdravljenja z zdravilom Eylea v 24. tednu (-79 mikronov v skupini, zdravljeni z zdravilom Eylea 2 mg oziroma -4 mikrone v kontrolni skupini), ki se je ohranila do 48. tedna.
English: Keep the syringe in the sterile tray until you are ready for assembly.
Slovenian: Brizgo shranjujte na sterilnem pladnju, dokler je ni potrebno sestaviti.
English: • Risk factors associated with the development of a retinal pigment epithelial tear after antiVEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Slovenian: • Dejavniki tveganja za zatrganje pigmentnega epitelija mrežnice pri zdravljenju vlažne starostne degeneracije makule z zaviralci VEGF sta obsežen in/ali visok odstop pigmentnega epitelija mrežnice.
English: Myopic CNV
Slovenian: CNV.
English: The excess volume should be expelled before injecting.
Slovenian: Presežni volumen je treba odstraniti pred injiciranjem.
English: In each study, patients were randomly assigned in a 1:1:1:1 ratio to 1 of 4 dosing regimens:
Slovenian: V obeh študijah so bolnike naključno razporedili v enega od treh režimov odmerjanja v razmerju 1:1:1:
English: F) Difference and 95% CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for country
Slovenian: Razlika in 95 % interval zaupanja (IZ) se izračunata s pomočjo Cochran-Mantel-Haenszelovega (CMH) testa, prilagojenega za državo (country designations).
English: The extractable volume of the syringe (90 microlitres) is not to be used in total.
Slovenian: Vsebina brizge (90 mikrolitrov) se ne porabi v celoti.
English: At week 100, the respective percentages were 32.6% and 37.1% of the Eylea 2Q8 groups and 8.2% and 15.6% of the control groups.
Slovenian: V 100. tednu je bil odstotek 32,6 % oziroma 37,1 % v skupinah, ki sta prejemali zdravilo Eylea 2Q8, ter 8,2 % oziroma 15,6 % v kontrolnih skupinah.
English: • Eylea is not recommended during breast-feeding.
Slovenian: • Uporabe zdravila Eylea se ne priporoča med dojenjem.
English: Eylea is given as an injection into your eye (intravitreal injection).
Slovenian: Zdravilo Eylea se injicira v oko (intravitrealna injekcija).
English: The difference between treatment groups was statistically significant in favour of Eylea for the primary endpoint (change in BCVA) and confirmatory secondary efficacy endpoint (proportion of patients who gained 15 letters in BCVA) at week 24 compared to baseline.
Slovenian: Razlika med zdravljenima skupinama je bila statistično značilna v korist zdravljenja z zdravilom Eylea za primarni cilj učinkovitosti (sprememba BCVA) in potrjena s sekundarnim ciljem učinkovitosti (delež bolnikov, ki so do 24. tedna pridobili 15 črk BCVA glede na izhodiščne vrednosti).
English: As with all therapeutic proteins, there is a potential for immunogenicity with Eylea.
Slovenian: Kot pri vseh terapevtskih proteinih obstaja tudi pri zdravilu Eylea možnost za razvoj imunogenosti.
English: Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists.
Slovenian: Dodatni odmerki se lahko uporabijo, če ocena ostrine vida in/ali anatomski izgled rumene pege kažeta, da je bolezen še prisotna.
English: In the second year of the studies, patients continued to receive the initially randomised dosage but on a modified dosing schedule guided by assessment of visual and anatomic outcomes with a protocoldefined maximum dosing interval of 12 weeks.
Slovenian: V drugem letu študij so bolniki še naprej prejemali odmerke v jakostih, v katere so bili randomizirani na začetku, vendar s spremenjenim režimom odmerjanja, glede na oceno ostrine vida in anatomski izgled rumene pege, z največjim intervalom odmerjanja 12 tednov, kar je bilo opredeljeno v protokolu.
English: In the aflibercept treatment group (n = 224) at week 52, this treatment regimen resulted in patients receiving a mean of 9.2 injections, which is similar to the administered number of doses in the Eylea 2Q8 group in VIVIDDME and VISTADME, while overall efficacy of the aflibercept treatment group in Protocol T was comparable to the Eylea 2Q8 group in VIVIDDME and VISTADME.
Slovenian: tedni tedni afliberceptom (N = 224) v 52. tednu, so bolniki po tem režimu zdravljenja prejeli povprečno 9,2 injekciji, kar je bilo podobno prejetemu številu odmerkov v skupini Eylea 2Q8 v VIVIDDME in VISTADME, medtem ko je bila učinkovitost v skupini, zdravljeni z afliberceptom v protokolu T primerljiva s skupino Eylea 2Q8 v VIVIDDME in VISTADME.
English: There is no relevant use of Eylea in the paediatric population for the indications of wet AMD, CRVO, BRVO, DME and myopic CNV.
Slovenian: Zdravilo Eylea ni primerno za uporabo pri pediatrični populaciji za indikacije vlažna AMD, CRVO, BRVO, DME in miopična CNV.
English: Please note: You should snap off (do not turn or twist) the syringe cap.
Slovenian: Opozorilo: zaščitno zaporko morate odlomiti (ne obračajte in ne zvijajte je).
English: • Physician information
Slovenian: • informacije za zdravnika
English: Eylea 2Q8 E) (Eylea 2 mg every 8 weeks following 3 initial monthly doses) (N = 607)
Slovenian: Izid učinkovitosti zdravilo Eylea 2Q8 E (zdravilo Eylea 2 mg vsakih 8 tednov po 3 začetnih mesečnih odmerkih) (N = 607)
English: In pharmacokinetic sub-studies in patients with CRVO, BRVO, DME or myopic CNV mean Cmax of free aflibercept in plasma were similar with values in the range of 0.03 to 0.05 microgram/ml and individual values not exceeding 0.14 microgram/ml.
Slovenian: V farmakokinetični podštudiji pri bolnikih s CRVO, BRVO, DME ali miopično CNV je bila povprečna vrednost Cmax prostega aflibercepta v plazmi podobna, v razponu od 0,03 do 0,05 mikrogramov/ml in posamezne vrednosti niso presegle 0,14 mikrogramov/ml.
English: Up-regulation of VEGF is associated with the breakdown of the blood retina barrier, increased vascular permeability, retinal oedema, and neovascularisation complications.
Slovenian: Povečano sproščanje VEGF je povezano z razpadanjem krvno-mrežnične pregrade, povečanjem prepustnosti žil, edemom mrežnice in zapleti neovaskularizacije.
English: In combined data analysis of GALILEO and COPERNICUS, Eylea demonstrated clinically meaningful changes from baseline in pre-specified secondary efficacy endpoint National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
Slovenian: V analizi združenih podatkov iz študij GALILEO in COPERNICUS, je zdravilo Eylea pokazalo klinično pomembne spremembe glede na izhodiščno stanje pri predhodno določenih sekundarnih ciljih učinkovitosti po National Eye institute Visual Function Questionnaire (NEI VFQ-25).
English: Prior to launch and during the product's lifecycle in each Member State the Marketing Authorisation Holder (MAH) will agree the final educational material with the National Competent Authority.
Slovenian: Imetnik dovoljenja za promet z zdravilom se bo pred prihodom na trg in med življenskim ciklusom zdravila s pristojnim nacionalnim regulatornim organom v vsaki državi članici dogovoril o končni različici izobraževalnega gradiva.
English: Since the pre-filled syringe contains more volume (90 microlitres) than the recommended dose (50 microlitres), a part of the volume contained in the syringe has to be discarded prior to the administration.
Slovenian: Ker napolnjena injekcijska brizga vsebuje večji volumen (90 mikrolitrov) kot je priporočeni odmerek (50 mikrolitrov), je treba odvečni del raztopine v brizgi zavreči pred uporabo.
English: - The other ingredients are: polysorbate 20, sodium dihydrogen phosphate monohydrate (for pH adjustment), disodium hydrogen phosphate heptahydrate (for pH adjustment), sodium chloride, sucrose, water for injection.
Slovenian: - Druge sestavine zdravila so: polisorbat 20, natrijev dihidrogenfosfat monohidrat (za uravnavanje pH), dinatrijev hidrogenfosfat heptahidrat (za uravnavanje pH), natrijev klorid, saharoza, voda za injekcije.
English: Table 1: All treatment-emergent adverse drug reactions reported in patients in phase III studies (pooled data of the phase III studies for the indications wet AMD, CRVO, BRVO, DME and myopic CNV) or during post-marketing surveillance
Slovenian: Preglednica 1: Vsi neželeni učinki zdravila, ki so se pojavili pri bolnikih med zdravljenjem v študijah III. faze (zbrani podatki iz študij III. faze za indikacije vlažna AMD, CRVO, BRVO, DME in miopična CNV) ali v obdobju trženja
English: Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
Slovenian: Aflibercept je pridobljen z rekombinantno DNK tehnologijo v K1 celicah jajčnika kitajskega hrčka.
English: Since the vial contains more volume (100 microlitres) than the recommended dose (50 microlitres), a part of the volume contained in the vial has to be discarded prior to the administration.
Slovenian: Ker viala vsebuje večji volumen (100 mikrolitrov) kot je priporočeni odmerek (50 mikrolitrov), je treba odvečni del raztopine v viali zavreči pred uporabo.
English: In both studies, patients were randomly assigned in a 3:2 ratio to either 2 mg Eylea administered every 4 weeks (2Q4), or the control group receiving sham injections every 4 weeks for a total of 6 injections.
Slovenian: V obeh študijah so bolnike naključno razporedili v razmerju 3:2 v skupino, ki je vsake 4 tedne prejemala 2 mg zdravila Eylea (2Q4) ali v kontrolno skupino, ki je vsake 4 tedne prejemala injekcije placeba, skupno 6 injekcij.
English: Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.
Slovenian: V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
English: When the macula swells with fluid, central vision becomes blurry.
Slovenian: Ko rumena pega zaradi tekočine nabrekne, se centralni vid zamegli.
English: With administration of Eylea, there may be some side effects affecting the eyes which are due to the injection procedure.
Slovenian: Pri injiciranju zdravila Eylea se lahko pojavijo nekateri neželeni učinki, ki prizadenejo oko in so povezani s postopkom injiciranja.
English: Your doctor will decide on the schedule for follow up examinations.
Slovenian: Zdravnik bo določil načrt nadaljnjih pregledov.
English: • Intravitreal injection procedure video
Slovenian: • video postopek intravitrealnega injiciranja
English: Aflibercept is slowly absorbed from the eye into the systemic circulation after intravitreal administration and is predominately observed in the systemic circulation as an inactive, stable complex with VEGF; however only “free aflibercept” is able to bind endogenous VEGF.
Slovenian: V sistemskem obtoku je na voljo predvsem kot neaktiven, stabilen kompleks z VEGF; na endogeni VEGF se lahko veže le "prosti aflibercept".
English: A secondary efficacy endpoint was change in visual acuity at week 24 compared to baseline, which was statistically significant in favour of Eylea in the VIBRANT study.
Slovenian: Spremenljivka sekundarne učinkovitosti je bila sprememba v ostrini vida v 24. tednu v primerjavi z izhodiščnim stanjem in je bila statistično značilna v korist zdravila Eylea v študiji VIBRANT.
English: Serious ocular adverse reactions in the study eye related to the injection procedure have occurred in less than 1 in 1,900 intravitreal injections with Eylea and included blindness, endophthalmitis, retinal detachment, cataract traumatic, cataract, vitreous haemorrhage, vitreous detachment, and intraocular pressure increased (see section 4.4).
Slovenian: Resni očesni neželeni učinki, povezani s postopkom injiciranja, ki so se pojavili v zdravljenem očesu, pri manj kot 1 od 1.900 intravitrealnih injekcij zdravila Eylea, so vključevali slepoto, endoftalmitis, odstop mrežnice, travmatsko katarakto, katarakto, krvavitev v steklovino, odstop steklovine in povišan intraokularni tlak (glejte poglavje 4.4).
English: • The dose should be withheld within the previous or next 28 days in the event of a performed or planned intraocular surgery.
Slovenian: • Z zdravljenjem je treba prenehati 28 dni pred načrtovano intraokularno operacijo in se ga lahko nadaljuje 28. dan po opravljeni intraokularni operaciji.
English: • What are the steps following treatment with Eylea
Slovenian: • koraki, ki bodo sledili po zdravljenju z zdravilom Eylea
English: The use of Eylea in children or adolescents under 18 has not been studied because wet AMD, CRVO, BRVO, DME and myopic CNV occur mainly in adults.
Slovenian: Uporabe zdravila Eylea pri otrocih in mladostnikih, starih manj kot 18 let, niso preučevali, ker se vlažna starostna degeneracija rumene pege, makularni edem, ki nastane kot posledica zapore centralne mrežnične vene ali veje mrežnične vene, diabetični makularni edem in miopična CNV pojavljajo predvsem pri odraslih.
English: Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility were observed at all dose levels.
Slovenian: Pri vseh odmerkih so opazili izostanek ali neredno menstruacijo, povezano s spremembo vrednosti ženskih spolnih hormonov, in spremenjeno morfologijo in gibljivost spermijev.
English: Post-authorisation efficacy study (PAES) To perform an interventional post-authorisation efficacy study in patients with diabetic macular oedema with the primary objective of comparing, after the first initial year of Eylea treatment, the standard regime of injections every 8 weeks with alternative treatment regimens, i.e. extended treatment intervals based on visual and anatomic outcomes (PRN and treat-and-extend).
Slovenian: Post-avtorizacijska študija učinkovitosti (PAES) Izvesti intervencijsko post-avtorizacijsko študijo učinkovitosti pri bolnikih z diabetičnim makularnim edemom, katere primarni cilj bo primerjati, po začetnem letu zdravljenja z zdravilom Eylea, standardni režim injiciranja vsakih 8 tednov z alternativnimi režimi zdravljenja tj. podaljšani intervali med injekcijami glede na oceno ostrine vida in anatomski izgled rumene pege (PRN in »zdraviti in podaljšati«)
English: You will start your treatment with a series of monthly Eylea injections.
Slovenian: Zdravljenje boste začeli s serijo injekcij zdravila Eylea, ki jih boste prejemali mesečno.
English: Furthermore, in the 4-week adjustment group 40.7% of patients were extended to 16 week intervals.
Slovenian: Pri 40,7 % bolnikov je bil v skupini, ki so ji interval med injekcijami podaljševali po 4 tedne, interval podaljšan na 16 tednov.
English: The MAH has agreed to provide EU Educational Material for Eylea.
Slovenian: Imetnik dovoljenja za promet se strinja, da se za zdravilo Eylea pripravi izobraževalno gradivo.
English: This increased incidence was comparable between patients treated with ranibizumab and Eylea.
Slovenian: Ta povečana pogostnost je bila primerljiva med bolniki, ki so prejemali ranibizumab in zdravilo Eylea.
English: To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid.
Slovenian: Da preprečite vnos zraka, zagotovite, da je poševni del filtrirne igle potopljen v tekočino.
English: Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition.
Slovenian: Arterijski trombembolični dogodki so neželeni učinki, ki so morda povezani s sistemskim zaviranjem VEGF.
English: Patient ages ranged from 42 to 94 years with a mean of 65 years.
Slovenian: Bolniki so bili stari od 42 do 94 let, v povprečju 65 let.
English: The fixed regimen for Eylea rescue was three times Eylea 2mg every 4 weeks followed by injections every 8 weeks.
Slovenian: Fiksen režim za rešilno zdravljenje z zdravilom Eylea je bil trikrat zdravilo Eylea 2 mg vsake 4 tedne, nato pa vsakih 8 tednov.
English: Some of these may be serious and include blindness, a serious infection or inflammation inside the eye (endophthalmitis), detachment, tear or bleeding of the light-sensitive layer at the back of the eye (retinal detachment or tear), clouding of the lens (cataract), bleeding in the eye (vitreous haemorrhage), detachment of the gel-like substance inside the eye from the retina (vitreous detachment) and increase of pressure inside the eye, see section 2.
Slovenian: Nekateri med njimi so lahko resni in vključujejo slepoto, resne okužbe in vnetja znotraj očesa (endoftalmitis), odstop, raztrganine ali krvavitve v na svetlobo občutljivo plast v zadnjem delu očesa (odstop ali raztrganine mrežnice), motnjavo leče (katarakta), krvavitve v očesu (krvavitve v steklovino), odstop gelu podobne snovi znotraj očesa od mrežnice (odstop steklovine) in povišanje očesnega tlaka, glejte poglavje 2.
English: The systemic exposure based on Cmax and AUC for free aflibercept were approximately 200and 700-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg. At the No Observed Adverse Effect Level (NOAEL) of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based on Cmax and AUC, respectively.
Slovenian: Sistemska izpostavljenost za prosti aflibercept glede na Cmax in AUC je bila približno 200-krat oziroma 700-krat večja v primerjavi z ustreznimi vrednostmi, ki so jih opazili pri ljudeh, po intravitrealnem odmerku 2 mg. Glede na NOAEL (No Observed Adverse Effect Level) je bila sistemska izpostavljenost pri opicah pri odmerku 0,5 mg/oko 42-krat večja glede na Cmax oziroma 56krat večja glede na AUC.
English: Your doctor will monitor this after each injection.
Slovenian: Zdravnik vam bo po vsaki injekciji izmeril očesni tlak.
English: • visual impairment due to diabetic macular oedema (DME) (see section 5.1),
Slovenian: • okvare vida zaradi diabetičnega makularnega edema (DME - Diabetic Macular Oedema) (glejte poglavje 5.1),
English: Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.4).
Slovenian: Ženske v rodni dobi morajo med zdravljenjem in še vsaj 3 mesece po zadnji intravitrealni injekciji aflibercepta uporabljati učinkovito kontracepcijo (glejte poglavje 4.4).
English: Mean Change in Visual Acuity from Baseline to Week 96 for the Combined Data from the View1 and View2 Studies
Slovenian: Povprečna sprememba ostrine vida glede na izhodiščne vrednosti do 96. tedna za združene podatke iz študij VIEW1 in VIEW2
English: Post-authorisation efficacy study (PAES) To perform a post-authorisation randomised study in patients with neovascular (wet) AMD with the primary objective of comparing the standard regime of injections every 8 weeks with a reactive regimen based on visual and anatomic outcomes, based on a CHMP approved protocol.
Slovenian: Post-avtorizacijska študija učinkovitosti (PAES) Izvesti post-autorizacijsko randomizirano študijo pri bolnikih z neovaskularno (vlažno) AMD, katere primarni cilj bo primerjati standardni režim injiciranja vsakih 8 tednov z režimom glede na oceno ostrine vida in anatomski izgled rumene pege, v skladu s protokolom, odobrenim s strani CHMP
English: In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline and the Eylea group was superior to laser control.
Slovenian: V študiji VIBRANT je bil primarni cilj učinkovitosti delež bolnikov, ki so pridobili vsaj 15 črk BCVA v 24. tednu v primerjavi z izhodiščnimi vrednostmi in zdravljenje z zdravilom Eylea je bilo superiorno v primerjavi s kontrolno skupino z laserskim zdravljenjem.
English: The schedule for monitoring should therefore be determined by the treating physician and may be more frequent than the schedule of injections.
Slovenian: Lečeči zdravnik mora zato določiti načrt spremljanja bolnika; pregledi so lahko pogostejši kot je načrtovano injiciranje zdravila.
English: • Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.6).
Slovenian: • Ženske v rodni dobi morajo med zdravljenjem in še vsaj 3 mesece po zadnji intravitrealni injekciji aflibercepta uporabljati učinkovito kontracepcijo (glejte poglavje 4.6).
English: In myopic CNV there is no experience with Eylea in the treatment of non-Asian patients, patients who have previously undergone treatment for myopic CNV, and patients with extrafoveal lesions.
Slovenian: Izkušenj z zdravljenjem miopične CNV z zdravilom Eylea pri neazijskih bolnikih, bolnikih, ki so že bili zdravljeni zaradi miopične CNV, in bolnikih z lezijami zunaj fovee (ekstrafovealne lezije), ni.
English: After the first 12 months of treatment with Eylea, the treatment interval may be extended based on your doctor's examination.
Slovenian: Glede na izvid zdravniškega pregleda pa se lahko po prvih 12 mesecih zdravljenja z zdravilom Eylea interval med injekcijami podaljša.
English: For the intravitreal injection, a 30 G x ½ inch injection needle should be used.
Slovenian: Za intravitrealno injekcijo je treba uporabiti injekcijsko iglo 30 G x 12,7 mm.
English: mean B,C,E
Slovenian: D,C,E
English: • Patient information packs
Slovenian: • paket izobraževalnih gradiv za bolnika
English: In the VIVIDDME and the VISTADME studies, a statistically significant greater mean decrease in CRT from baseline to week 52 was observed in patients treated with Eylea than with the laser control,192.4 and -183.1 microns for the 2Q8 Eylea groups and -66.2 and -73.3 microns for the control groups, respectively.
Slovenian: V študijah VIVIDDME in VISTADME so opazili statistično značilno večje povprečno zmanjšanje CRT glede na izhodiščne vrednosti do 52. tedna v skupinah, ki so prejemale zdravilo Eylea kot v kontrolnih skupinah z laserskim zdravljenjem (-192,4 oziroma -183,1 mikronov v skupinah, ki so prejemale zdravilo Eylea 2Q8, ter -66,2 oziroma -73,3 mikronov v kontrolnih skupinah).
English: Eylea should not be used during pregnancy unless the potential benefit outweighs the potential risk to the unborn child.
Slovenian: Zdravila Eylea se ne sme uporabljati med nosečnostjo, razen če so možne koristi večje od možnega tveganja za še nerojenega otroka.
English: Other medicines and Eylea Tell your doctor if you are using, have recently used or might use any other medicines.
Slovenian: Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: Figure 3: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 52 in VIBRANT Study
Slovenian: Slika 3: Povprečna sprememba BCVA, ocenjena z ETDRS tablicami, glede na izhodiščne vrednosti do 52. tedna v študiji VIBRANT
English: Patients were randomly assigned in a 3:1 ratio to receive either 2 mg Eylea intravitreally or sham injections administered once at study start with additional injections given monthly in case of disease persistence or recurrence until week 24, when the primary endpoint was assessed.
Slovenian: Bolnike so naključno razporedili v razmerju 3:1 v skupino, ki je prejela intravitrealno injekcijo 2 mg zdravila Eylea ali injekcijo placeba na začetku študije, dodatne injekcije pa so prejeli enkrat mesečno do 24. tedna v primeru, da je bolezen vztrajala ali se ponovila.
English: Attach the 18 G, 5-micron filter needle supplied in the carton to a 1-ml sterile, Luer-lock syringe.
Slovenian: Pritrdite 5-mikronsko filtrirno iglo 18 G, priloženo v škatli, na sterilno 1-ml Luer Lock brizgo.
English: • Key signs and symptoms of serious adverse events including endophthalmitis, intraocular pressure increased, retinal pigment epithelial tear and cataract
Slovenian: • ključne znake in simptome resnih neželenih učinkov, vključno z endoftalmitisom, povišanim intraokularnim tlakom, zatrganjem pigmentnega epitelija mrežnice in katarakto